Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 4/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | PDE1A | P54750 | 1/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.41 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL943645 | 0.97 | CNR2 (0.48) | PTGDR2SLC6A9CNR2PDE4APDE4B | |
| SCHEMBL16961586 | 0.86 | CXCR5 (0.43) | PTGDR2SLC6A9CNR2PDE4APDE4B | |
| SCHEMBL29825320 | 0.82 | MAP3K5 (0.42) | PTGDR2SLC6A9CXCR5 | |
| SCHEMBL23287020 | 0.82 | MAP3K5 (0.42) | PTGDR2SLC6A9CXCR5 | |
| SCHEMBL943472 | 0.82 | CNR2 (0.48) | SLC6A9CNR2PDE4BPDE5APDE1A | |
| SCHEMBL26388239 | 0.81 | CNR2 (0.44) | PTGDR2SLC6A9CNR2 | |
| SCHEMBL26388243 | 0.81 | GSK3B (0.45) | PTGDR2SLC6A9CNR2 | |
| SCHEMBL24371188 | 0.79 | HCRTR1 (0.44) | SLC6A9CNR2PDE5A | |
| SCHEMBL24371182 | 0.78 | GPR6 (0.43) | PTGDR2SLC6A9CNR2 | |
| SCHEMBL28807605 | 0.78 | HRH3 (0.43) | PTGDR2SLC6A9PDE4BMAOBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319099-B2 | Such as 1-{3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl benzoyl)-piperazin-1-yl]-phenyl}-ethanone for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | disclosed |
| EP-1656361-B1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-01-02 | — | — | EP | disclosed |
| US-20050209241-A1 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209241-A1 | Benzoyl-piperazine derivatives | SLC1A2, SLC18A2, SLC6A7 | PTGDR2 383/4885SLC6A9 82/4885CNR2 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.